Fusion protein · Protein replacement · developed by Larimar Therapeutics
Nomlabofusp (CTI-1601) is a recombinant fusion protein designed to deliver human frataxin, the protein deficient in Friedreich's ataxia. It is given by subcutaneous injection and is studied in Friedreich's ataxia.
Summary written with AI from the sources listed at the end of this page.
| Trial | Phase | Condition | Status | Sponsor |
|---|---|---|---|---|
| NCT07778836 | Phase 3 | Friedreich Ataxia | Recruiting | LRMR |
| NCT06447025 | Phase 2 | Friedreich Ataxia | Recruiting | LRMR |
Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.
Friedreich AtaxiaFriedreich's Ataxia
Updated Oct 18, 2026. Something wrong or missing? Report it on the LRMR page.
See LRMR's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.
LRMR catalysts and pipeline →